Impact Capital Partners LLC Acquires Shares of 954 Thermo Fisher Scientific Inc. (NYSE:TMO)

Impact Capital Partners LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 954 shares of the medical research company’s stock, valued at approximately $496,000.

Several other large investors have also bought and sold shares of the stock. Commonwealth Equity Services LLC increased its stake in Thermo Fisher Scientific by 2.3% in the 4th quarter. Commonwealth Equity Services LLC now owns 109,749 shares of the medical research company’s stock worth $57,095,000 after acquiring an additional 2,478 shares during the last quarter. PGGM Investments grew its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. PGGM Investments now owns 204,322 shares of the medical research company’s stock valued at $106,294,000 after purchasing an additional 532 shares during the last quarter. Bowen Hanes & Co. Inc. grew its holdings in Thermo Fisher Scientific by 8.7% in the 4th quarter. Bowen Hanes & Co. Inc. now owns 128,066 shares of the medical research company’s stock worth $66,624,000 after acquiring an additional 10,250 shares during the last quarter. Tredje AP fonden grew its holdings in Thermo Fisher Scientific by 19.7% in the 4th quarter. Tredje AP fonden now owns 145,557 shares of the medical research company’s stock worth $75,723,000 after acquiring an additional 23,968 shares during the last quarter. Finally, Vestcor Inc lifted its position in shares of Thermo Fisher Scientific by 6.6% in the 4th quarter. Vestcor Inc now owns 11,754 shares of the medical research company’s stock worth $6,115,000 after purchasing an additional 723 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $508.62 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The business’s 50-day simple moving average is $548.72 and its two-hundred day simple moving average is $560.10. The stock has a market cap of $191.88 billion, a PE ratio of 30.77, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has authorized a share buyback program on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.34%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.41%.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock worth $13,106,062 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Scotiabank raised their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research report on Monday, February 3rd. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Wells Fargo & Company upped their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Citigroup lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Raymond James reaffirmed an “outperform” rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.